Dr. Adhikari’s Ph.D. was focused on the epidemiology and genetics of community-acquired Methicillin Resistant S. aureus (MRSA) from the University of Otago, New Zealand, under the supervision of Prof. Gregory M. Cook.

As a part of his Ph. D., he got further training in the laboratory of the pioneer MRSA scientist, Prof. Brigitte Berger-Baechi at the University of Zurich, Switzerland.

He completed his postdoctoral research at the New York University (NYU) medical center under Prof. Richard P. Novick, a member of the National academy of science and a pioneering staphylococcal researcher. His work at NYU focused on the quorum sensing system and the regulation of toxin production in S. aureus.

For the last 13 years, he has been involved in a vaccine, therapeutics, and antimicrobial research at IBT. He secured and completed four NIAID-funded SBIR/STTR phase I and is working on a STTR phase II grant currently as a Principal Investigator.

Over the past several years, he has worked extensively with antibody therapeutics and engineered various fusion antibodies in collaboration with different universities such as Harvard, the University of Maryland, Tulane, and many others.

He has lead a collaborative product development project with Emergent and worked closely with many other companies on similar projects. He is also a guest editor of Microorganism, Antibiotics, and Frontier in Immunology journals.